Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cross-presentation is one of the main features of dendritic cells (DCs), which is critically important for the development of spontaneous and therapy-inducible antitumor immune responses. Patients, at early stages of cancer, have normal presence of DCs. However, the difficulties in the development of antitumor responses in patients with low tumor burden raised the question of the mechanisms of DC dysfunction. In this study, we found that, in differentiated DCs, tumor-derived factors blocked the cross-presentation of exogenous Ags without inhibiting the Ag presentation of endogenous protein or peptides. This effect was caused by intracellular accumulation of different types of oxidized neutral lipids: triglycerides, cholesterol esters, and fatty acids. In contrast, the accumulation of nonoxidized lipids did not affect cross-presentation. Oxidized lipids blocked cross-presentation by reducing the expression of peptide-MHC class I complexes on the cell surface. Thus, this study suggests the novel role of oxidized lipids in the regulation of cross-presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“hypoxic tumors have been shown to exhibit decreased MHC-I expression in tumor cells and DCs (Ramakrishnan et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ramakrishnan et al., 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“generation of cells with immune-suppressive activity, including regulatory DCs and myeloid-derived suppressor cells (4).”
BackgroundSelf-citationBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Lipid Droplets and Cellular Lipid Metabolism
Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,661 · cited 1×
“The presence and size of LBs is defined by the accumulation of FA precursors and their esterification into TAGs and CEs, the major constituents of the hydrophobic core of LBs (26).”
BackgroundCross-presentation by dendritic cells
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637 · cited 2×
“The endogenous pathway of presentation invariably depends on proteasomes, whereas the pathway of cross-presentation (cytosolic or vacuolar) depends on the type of Ag and the mechanism of its uptake (12, 35).”
BackgroundMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Self-citationBevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956 · cited 1×
“generate peptide T cell epitopes that are presented by MHC class I (MHC-I) molecules (9, 10).”
BackgroundLipid accumulation and dendritic cell dysfunction in cancer
Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H.-I., Celis, E., Lennox, B., et al. (2010) · Nature Medicine · doi:10.1038/nm.2172 · Cited by 735
Self-citationEndoplasmic Reticulum-Mediated Phagocytosis Is a Mechanism of Entry into Macrophages
Gagnon, E., Duclos, S., Rondeau, C., Chevet, E., Cameron, P. H., Steele-Mortimer, O., Paiement, J., Bergeron, J. J. M., & Desjardins, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00797-3 · Cited by 683 · cited 1×
“In addition to recycling MHC-I, transport of MHC-I, from ER to the endocytic compartment, has also been demonstrated (49, 50).”
BackgroundMechanisms and Consequences of Dendritic Cell Migration
Alvarez, D., Vollmann, E. H., & von Andrian, U. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.006 · Cited by 525
Cited by
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
Friedmann Angeli, J. P., Krysko, D. V., & Conrad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0149-1 · Cited by 1,259
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
“Like macrophages in atherosclerotic plaques, DCs in the tumor can accumulate oxidized lipoproteins through scavenger receptor mediated internalization and formation of lipid droplets, which can ultimately impair their ability to cross-present tumor antigens and activate T cells (Cubillos-Ruiz et al., 2015; Ramakrishna…”
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
“showed that various oxidized lipids in DCs, blocked the cross-presentation of exogenous antigens by reducing the expression of MHCI complexes on cell surface.(349)”
BackgroundTurning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
Self-citationER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933
“Abnormal intracellular accumulation of peroxidized lipids is a common feature of dysfunctional DCs infiltrating several human and murine cancers (Herber et al., 2010; Ramakrishnan et al., 2014).”
BackgroundInfluentialCholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921
Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer
Cubillos-Ruiz, J. R., Bettigole, S. E., & Glimcher, L. H. (2017) · Cell · doi:10.1016/j.cell.2016.12.004 · Cited by 895
Fatty acid transport protein 2 reprograms neutrophils in cancer
Veglia, F., Tyurin, V. A., Blasi, M., De Leo, A., Kossenkov, A. V., Donthireddy, L., To, T. K. J., Schug, Z., Basu, S., Wang, F., et al. (2019) · Nature · doi:10.1038/s41586-019-1118-2 · Cited by 751
Self-citationThe interaction between ferroptosis and lipid metabolism in cancer
Li, D., & Li, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00216-5 · Cited by 703
“Moreover, oxidized lipids and lipid bodies containing oxidative truncated lipids in DCs can inhibit crosspresentation in cancer.(124,125) The 12/15-LOX–derived lipid mediators limit the maturation process of DCs and dampen the differentiation of Th17 cells.”
BackgroundDendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 598
“Abnormal accumulation of lipids in DCs has emerged as an important mechanism for DC dysfunction, as TIDCs from multiple tumor models and cancer patients exhibited reduced capacity in crosspresentation because of lipid accumulation (98, 99).”
BackgroundHossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
The role of lipids in cancer progression and metastasis
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 563
Lipid droplets: platforms with multiple functions in cancer hallmarks
Cruz, A. L. S., Barreto, E. D. A., Fazolini, N. P. B., Viola, J. P. B., & Bozza, P. T. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2297-3 · Cited by 535
Pearce, E. J., & Everts, B. (2015) · Nature Reviews Immunology · doi:10.1038/nri3771 · Cited by 483
Lipids in the tumor microenvironment: From cancer progression to treatment
Corn, K. C., Windham, M. A., & Rafat, M. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101055 · Cited by 469
Dendritic cells in cancer: the role revisited
Veglia, F., & Gabrilovich, D. I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.002 · Cited by 443
Self-citationCancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
Wiernicki, B., Maschalidi, S., Pinney, J., Adjemian, S., Vanden Berghe, T., Ravichandran, K. S., & Vandenabeele, P. (2022) · Nature Communications · doi:10.1038/s41467-022-31218-2 · Cited by 420
CD36 tango in cancer: signaling pathways and functions
Wang, J., & Li, Y. (2019) · Theranostics · doi:10.7150/thno.36037 · Cited by 368
“As compared with DCs from tumor-free mice and healthy people, the DCs of tumor-bearing mice and cancer patients have been reported to contain a considerably larger proportion of triglycerides [120].”
ResultAl-Khami, A. A., Zheng, L., Del Valle, L., Hossain, F., Wyczechowska, D., Zabaleta, J., Sanchez, M. D., Dean, M. J., Rodriguez, P. C., & Ochoa, A. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344804 · Cited by 346
“factors, consistent with data indicating that these factors induce lipid uptake and accumulation in tumor-associated DC.(15,16)”
BackgroundResultInfluentialVeglia, F., Tyurin, V. A., Mohammadyani, D., Blasi, M., Duperret, E. K., Donthireddy, L., Hashimoto, A., Kapralov, A., Amoscato, A., Angelini, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02186-9 · Cited by 308
Self-citationMetabolic adaptation of lymphocytes in immunity and disease
Chapman, N. M., & Chi, H. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.012 · Cited by 305
The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules
Cruz, F. M., Colbert, J. D., Merino, E., Kriegsman, B. A., & Rock, K. L. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055254 · Cited by 299
Ferroptosis in the tumor microenvironment: perspectives for immunotherapy
Xu, H., Ye, D., Ren, M., Zhang, H., & Bi, F. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.014 · Cited by 294
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy
Liu, X., Hartman, C. L., Li, L., Albert, C. J., Si, F., Gao, A., Huang, L., Zhao, Y., Lin, W., Hsueh, E. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6314 · Cited by 274
“Recent studies have shown that LDs accumulate in tumor-derived DCs, which results in tolerogenic functions (30, 31).”
BackgroundAntigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 266
“Moreover, soluble factors within the TME limit the formation of MHC class I complexes and impair the antigen-presenting ability of DCs by upregulating their oxidized neutral lipid content [114].”
BackgroundFunctional states of myeloid cells in cancer
van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E., & Gabrilovich, D. I. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.009 · Cited by 261
Self-citationPeña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Molecular and Cellular Functions of CTLA-4
Van Coillie, S., Wiernicki, B., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 243
Metabolic Control of Dendritic Cell Functions: Digesting Information
Wculek, S. K., Khouili, S. C., Priego, E., Heras-Murillo, I., & Sancho, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00775 · Cited by 215
Lipid Droplets as Immune Modulators in Myeloid Cells
den Brok, M. H., Raaijmakers, T. K., Collado-Camps, E., & Adema, G. J. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.01.012 · Cited by 203
Dendritic Cell Metabolism and Function in Tumors
Giovanelli, P., Sandoval, T. A., & Cubillos-Ruiz, J. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.004 · Cited by 187
A twist of FATe: Lipid droplets and inflammatory lipid mediators
Jarc, E., & Petan, T. (2020) · Biochimie · doi:10.1016/j.biochi.2019.11.016 · Cited by 176
PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction
Yin, X., Zeng, W., Wu, B., Wang, L., Wang, Z., Tian, H., Wang, L., Jiang, Y., Clay, R., Wei, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108278 · Cited by 174
“Interestingly, TIDCs exhibit a “lacy” phenotype featuring highly enriched lipid droplets (LDs), and lipidladen TIDCs display an impaired potential to present tumor-associated antigens (TAAs) (Ramakrishnan et al., 2014).”
BackgroundInfluentialEverts, B., & Pearce, E. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00203 · Cited by 174
“Additionally, yet unidentified tumor-derived factors can promote aberrant lipid accumulation in DCs, resulting in impaired T cell priming (69, 70).”
BackgroundJiang, M., Qiao, M., Zhao, C., Deng, J., Li, X., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-341 · Cited by 157
“21037/tlcr-20-341 antitumor immunity (60).”
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D., & Merad, M. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 170
“260,261).”
Metabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P.-C. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 169
Yan, D., Adeshakin, A. O., Xu, M., Afolabi, L. O., Zhang, G., Chen, Y. H., & Wan, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01399 · Cited by 170
“demonstrated that accumulation of oxidized lipids in tumor-infiltrating CD11c DCs blocks antigen presentation and their orientation on major histocompatibility complex (MHC) class II (51, 52).”
BackgroundLiu, W.-W., Zheng, S.-Q., Li, T., Fei, Y.-F., Wang, C., Zhang, S., Wang, F., Jiang, G.-M., & Wang, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01777-5 · Cited by 166
“398 Knock-down of YTHDF1 enhances cross-presentation of DCs to CD8 + T cells by suppressing cathepsins expression, further increased IFN-γ secretion of T cells upregulates PD-L1 level in tumor cells.”
BackgroundInfluentialImmunogenic ferroptosis and where to find it?
Demuynck, R., Efimova, I., Naessens, F., & Krysko, D. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003430 · Cited by 168
Petan, T. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_51 · Cited by 165
“Moreover, since TAGs stored within lipid droplets may also be oxidized, it is possible that lipid droplets themselves are sites of lipid peroxidation that promote ferroptosis if peroxidized lipids are not efficiently removed (Ramakrishnan et al. 2014; Veglia et al. 2017).”
BackgroundPlebanek, M. P., Xue, Y., Nguyen, Y.-V., DeVito, N. C., Wang, X., Holtzhausen, A., Beasley, G. M., Theivanthiran, B., & Hanks, B. A. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi4191 · Cited by 164
“This finding is consistent with our functional data for CD63 + mregDCs, given that previous studies have demonstrated that oxidized lipids interfere with antigen processing and peptide MHC class I formation ( 23 ).”
BackgroundResultHuang, L., Xu, H., & Peng, G. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2018.4 · Cited by 164
Hu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12772 · Cited by 164
Immune and non-immune functions of adipose tissue leukocytes
Trim, W. V., & Lynch, L. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00635-7 · Cited by 164
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 165
Jiang, L., Fang, X., Wang, H., Li, D., & Wang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02927 · Cited by 159
Ugolini, A., Tyurin, V. A., Tyurina, Y. Y., Tcyganov, E. N., Donthireddy, L., Kagan, V. E., Gabrilovich, D. I., & Veglia, F. (2020) · JCI Insight · doi:10.1172/jci.insight.138581 · Cited by 158
“We and others have found that accumulation of lipids dramatically affected the antigen cross-presentation by cDC1 resulting in an impaired induction of specific anti-tumor CD8+ T cell responses (10-13).”
BackgroundSelf-citationden Brok, M. H., Büll, C., Wassink, M., de Graaf, A. M., Wagenaars, J. A. L., Minderman, M., Thakur, M., Amigorena, S., Rijke, E., Schrier, C. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13324 · Cited by 152
“Likewise, the presence of oxidized lipids in LBs was shown to hamper DC functionality and antigen presentation abilities 55 .”
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy
Zhang, S., Lv, K., Liu, Z., Zhao, R., & Li, F. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01807-9 · Cited by 153
“Accumulation of oxidized lipids, including fatty acids, in DC cells blocks cross-presentation of antigens by reducing the expression of surface MHCI complexes [123].”
BackgroundAl-Khami, A. A., Hossain, F., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Del Valle, L., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o18 · Cited by 150
Ferroptosis of immune cells in the tumor microenvironment
Kim, R., Taylor, D. K., Vonderheide, R. H., & Gabrilovich, D. I. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.005 · Cited by 150
Self-citationMetabolic Reprogramming of Immune Cells in the Tumor Microenvironment
Wang, J., He, Y., Hu, F., Hu, C., Sun, Y., Yang, K., & Yang, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212223 · Cited by 147
Cross-Presentation in Mouse and Human Dendritic Cells
Segura, É., & Amigorena, S. (2015) · Advances in immunology · doi:10.1016/bs.ai.2015.03.002 · Cited by 143
Targeting myeloid cells in the tumor sustaining microenvironment
Schupp, J., Krebs, F. K., Zimmer, N., Trzeciak, E., Schuppan, D., & Tuettenberg, A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.013 · Cited by 126
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 138
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 136
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy
Lian, X., Yang, K., Li, R., Li, M., Zuo, J., Zheng, B., Wang, W., Wang, P., & Zhou, S. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01486-5 · Cited by 133
“T cells primed by DCs with high level of intracellular lipids show reduced capacity of proliferation [47].”
BackgroundSTAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
Su, Y.-L., Banerjee, S., White, S. V., & Kortylewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061803 · Cited by 123
Hajihosseini, R., Asef‐Kabiri, L., Yousefi, H., Sarvnaz, H., Salehi, M., Akbari, M. E., & Eskandari, N. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01376-w · Cited by 131
“Indeed, it has been shown that DCs with a higher load of lipids have the defective ability in processing and crosspresentation of exogenous antigens [106, 107].”
BackgroundLipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer
Luo, Q., Zheng, N., Jiang, L., Wang, T., Zhang, P., Liu, Y., Zheng, P., Wang, W., Xie, G., Chen, L., et al. (2020) · Cancer Science · doi:10.1111/cas.14616 · Cited by 126
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 126
“Through the binding of chaperone heat shock protein 70, oxidatively truncated lipids prevent the translocation of peptide-MHCI to the cell surface, thus inhibiting cross-presentation while not affecting endogenous antigen presentation [95,96].”
BackgroundZheng, Y., Sun, L., Guo, J., & Ma, J. (2023) · 癌症:英文版 · doi:10.1002/cac2.12487 · Cited by 125
“The possible mechanism underlying the inhibitory effect of lipid droplets on DCs’ function is that the oxidative products in lipid droplets interacted with HSP70, thereby preventing the presentation of peptide-MHC-I complexes on the surface of DCs [135, 136].”
Niavarani, S. R., Lawson, C., Bakos, O., Boudaud, M., Batenchuk, C., Rouleau, S., & Tai, L.-H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6045-y · Cited by 114
“tional Dendritic Cells (cDC) has been reported [31, 32].”
BackgroundMetabolic regulation of ferroptosis in the tumor microenvironment
Mbah, N. E., & Lyssiotis, C. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101617 · Cited by 120
“Additionally, the accumulation of oxidized lipids in dendritic cells has been shown to diminish the expressionof peptide-MHCI complex and impair cross-presentationof exogenous tumor antigen (101).”
BackgroundcGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 121
Rodvold, J. J., Chiu, K., Hiramatsu, N., Nussbacher, J. K., Galimberti, V., Mahadevan, N. R., Willert, K., Lin, J. H., & Zanetti, M. (2017) · Science Signaling · doi:10.1126/scisignal.aah7177 · Cited by 120
“Recent reports emphasized the role of by-products of lipid oxidation (74, 75) as responsible actors in phenomena closely related”
BackgroundMolecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 113
“As compared with normal DCs from tumorfree mice, lipid-laden DCs stimulated T cells poorly because of defects in antigen cross presentation and increased production of IL-10 [19, 185].”
Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 114
Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
Bleve, A., Durante, B., Sica, A., & Consonni, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165845 · Cited by 111
Lipid Metabolism in Oncology: Why It Matters, How to Research, and How to Treat
Matsushita, Y., Nakagawa, H., & Koike, K. (2021) · Cancers · doi:10.3390/cancers13030474 · Cited by 110
“Tumor-derived factors result in the accumulation of oxidized lipids such as CE, TAG, and FA, which reduce major histocompatibility complex (MHC) class I complexes on the surface of dendritic cells and decrease antigen presentation [161].”
BackgroundIdentification the ferroptosis-related gene signature in patients with esophageal adenocarcinoma
Zhu, L., Yang, F., Wang, L., Dong, L., Huang, Z., Wang, G., Chen, G., & Li, Q. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01821-2 · Cited by 110
“Researchers found DCs in tumor-bearing hosts accumulate plenty of lipids and PUFAs, causing the impaired ability to present the antigen and stimulate the inadequate CD8+ T cells responses [35, 36].”
BackgroundUnfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
Cubillos-Ruiz, J. R., Mohamed, E., & Rodriguez, P. C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0203-4 · Cited by 96
Trial watch: chemotherapy-induced immunogenic cell death in oncology
Sprooten, J., Laureano, R. S., Vanmeerbeek, I., Govaerts, J., Naulaerts, S., Borràs, D., Kinget, L., Fucikova, J. P., Špíšek, R., Jelinkova, L. P., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2219591 · Cited by 107
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, Á., Cueto, F. J., Garasa, S., Perez‐Gracia, J. L., Sánchez-Arráez, Á., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx727 · Cited by 103
Fat, fight, and beyond: The multiple roles of lipid droplets in infections and inflammation
Pereira-Dutra, F. S., Teixeira, L., de Souza Costa, M. F., & Bozza, P. T. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0119-035r · Cited by 99
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy
Lv, Y., Li, Z., Liu, S., Zhou, Z., Jinling, S., Ba, Y., Weng, S., Zuo, A., Xu, H. W., Luo, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02407-6 · Cited by 98
FSP1-mediated lipid droplet quality control prevents neutral lipid peroxidation and ferroptosis
Lange, M., Wölk, M., Li, V. W., Doubravsky, C. E., Hendricks, J. M., Kato, S., Otoki, Y., Styler, B. S., Johnson, S. L., Harris, C. A., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01790-y · Cited by 99
“Truncated forms and hydroxyl derivatives of TGs have been observed in dendritic cells in cancer and hypoxic trophoblast cells 41,45,46 , although their importance remains to be determined.”
Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
Gao, A., Liu, X., Lin, W., Wang, J., Wang, S., Si, F., Huang, L. J., Zhao, Y., Sun, Y., & Peng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001536 · Cited by 94
Prospects for ferroptosis therapies in cancer
Ubellacker, J. M., & Dixon, S. J. (2025) · Nature Cancer · doi:10.1038/s43018-025-01037-7 · Cited by 91
Lipid metabolism in dendritic cell biology
You, Z., & Chi, H. (2023) · Immunological Reviews · doi:10.1111/imr.13215 · Cited by 88
Protein Quality Control in the Endoplasmic Reticulum and Cancer
Moon, H. W., Han, H. G., & Jeon, Y. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103020 · Cited by 88
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Lipid Droplets, the Central Hub Integrating Cell Metabolism and the Immune System
Zhang, W., Xu, L., Zhu, L., Liu, Y., Yang, S., & Zhao, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.746749 · Cited by 81
Energy metabolic pathways control the fate and function of myeloid immune cells
Al-Khami, A. A., Rodríguez, P. C., & Ochoa, A. C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.1vmr1216-535r · Cited by 80
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
Bujanda, Z. A. L., & Drake, C. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-491rr · Cited by 78
Caronni, N., Piperno, G. M., Simoncello, F., Romano, O., Vodret, S., Yanagihashi, Y., Dress, R. J., Dutertre, C., Bugatti, M., Bourdeley, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22535-z · Cited by 76
Lipid Quality Control and Ferroptosis: From Concept to Mechanism
Li, Z., Lange, M., Dixon, S. J., & Olzmann, J. A. (2023) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-033527 · Cited by 75
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 73
Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy
Luo, Z., Eichinger, K. M., Zhang, A., & Li, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216396 · Cited by 72
Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
Prete, A. D., Sozio, F., Barbazza, I., Salvi, V., Tiberio, L., Laffranchi, M., Gismondi, A., Bosisio, D., Schioppa, T., & Sozzani, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113930 · Cited by 72
Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 67
“Subsequent studies revealed that lipid accumulation in tumor-associated DC defective in cross-presentation resulted from an increase in polyunsaturated fatty acids, particularly linoleic acid and to a lesser extent arachidonic acid, and that DC isolated from tumor-bearing mice or exposed to tumor explant supernatants…”
BackgroundMetabolic reprogramming of immune cells in pancreatic cancer progression
Xiang, H., Yang, R., Tu, J., Yan, X., Yang, S., Lv, L., Zhai, X., Zhu, Y., Dong, D., & Tao, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113992 · Cited by 68
Metadata
- Authors
- Cao, W., Ramakrishnan, R., Tuyrin, V. A., Veglia, F., Condamine, T., Amoscato, A., Mohammadyani, D., Johnson, J. J., Min Zhang, L., Klein-Seetharaman, J., Celis, E., Kagan, V. E., & Gabrilovich, D. I.
- Affiliations
- Moffitt Cancer Center (US)
- University of Pittsburgh (US)
- The Wistar Institute (US)
- Molecular Core, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL 33612
- Division of Metabolic and Vascular Health, Medical School, University of Warwick , Coventry CV4 7AL,
- Corresponding author
- Gabrilovich, Dmitry I
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03
- Volume
- 192
- Issue
- 6
- Pages
- 2920-2931
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3998104
- OpenAlex
- W2149025737
- Cited by
- 302
- References
- 53
- Citations by year
- 2026: 28 · 2025: 36 · 2024: 27 · 2023: 24 · 2022: 40 · 2021: 48 · 2020: 29 · 2019: 21 · 2018: 13 · 2017: 21 · 2016: 7 · 2015: 5 · 2014: 3
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA165065, R01CA136828, R01CA165065, P30CA010815)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- oxidized lipids, cross-presentation, dendritic cells, dendritic cell dysfunction, antitumor immunity, triglycerides, cholesterol esters, fatty acids, peptide-MHC class I complexes, tumor-derived factors, tumor immunology
- MeSH terms
- Acetylcysteine, Animals, Histocompatibility Antigens Class II, Cells, Cultured, Dendritic Cells, Flow Cytometry, Humans, Interferon-gamma, Lipids, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Ovalbumin, Oxidation-Reduction, Peptide Fragments, Histocompatibility Antigens Class I, Cysteine Proteinase Inhibitors, Culture Media, Conditioned, Antigen Presentation, Microscopy, Confocal, Cross-Priming, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.